Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Medical Devices
Overview
Conditions
Intellectual Property
Research
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Overview

Designer Diagnostics Medical DevicesDesigner Diagnostics (website) is a wholly-owned medical devices subsidiary of Nutra Pharma Corporation. The Company was established in 2005 for the marketing and sales of rapid diagnostics test kits for infectious diseases, including Tuberculosis and NonTuberculous Mycobacteria (NTM).

Designer Diagnostics Test Kits provide a highly cost effective, highly efficient, low infrastructure solution for identifying and testing sensitivity of Nontuberculous Mycobacteria (NTM) that are capable of utilizing paraffin wax as a sole carbon source or those that are hydrophobic. Additionally Designer Diagnostics provides an efficient solution for the rapid identification and sensitivity testing of Tuberculosis (TB).

Benefits of the Designer Diagnostics' Test Kits:

  • Ability to provide much earlier diagnosis. (less than 1 week)
  • Long shelf life
  • Can be stored in extremely hostile environments
  • Cost effective compared to all other traditional methods
  • Does not require new large capital expenditures
  • Can be easily integrated into any lab environment from the most advanced to a simple mobile lab
  • Results can be quickly translated into PCR testing and other antibiotic sensitivity testing techniques
 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
July 15, 2015
Nutra Pharma Announces the Submission of Their First Orphan Drug Application to the US Food and Drug Administration (FDA)


July 10, 2015
SeeThruEquity Initiates Coverage on Nutra Pharma Corporation with a Price Target of $0.53


June 30, 2015
Nutra Pharma Announces Engagement of Investment Banking Firm Pickwick Capital Partners to Provide Strategic Advisory Services


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics